Back to top

Invo BioScience Inc. (INVO)

(Delayed Data from NSDQ)

$4.40 USD


+0.14 (3.29%)

Updated Aug 2, 2021 03:59 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy25.57%
5Strong Sell3.16%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 15% (214 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Trades from $1

Company Summary

INVO Bioscience is a medical device company, headquartered in Beverly, Massachusetts, focused on creating simplified, lower cost treatment options for patients diagnosed with infertility. It engages in the development and manufacture of its lead product, INVOcell, a novel medical device used in infertility treatment that enables egg fertilization and early embryo development in the woman's vaginal cavity. The company was founded by Claude Ranoux, MD, a noted expert in the field of reproductive health, infertility and embryology. INVO Bioscience focuses on selling its product to IVF centers and physicians through distributors, as well as directly to physicians in Europe, Canada, Latin America, and the Middle East.

General Information

Invo BioScience Inc.



Phone: 978-878-9505

Fax: NA



Industry Medical - Biomedical and Genetics
Sector Medical
Fiscal Year End December
Last Reported Quarter 6/30/2021
Next EPS Date 8/12/2021

EPS Information

Current Quarter EPS Consensus Estimate -0.19
Current Year EPS Consensus Estimate -0.66
Estimated Long-Term EPS Growth Rate 20.00
Next EPS Report Date 8/12/2021

Price and Volume Information

Zacks Rank Premium
Yesterday's Close 4.26
52 Week High 7.36
52 Week Low 2.90
Beta -1.13
20 Day Moving Average 23,560.05
Target Price Consensus 5.88


% Price Change
4 Week -6.58
12 Week 12.10
YTD 41.53
% Price Change Relative to S&P 500
4 Week -7.49
12 Week 7.96
YTD 20.95
Share Information
Shares Outstanding (millions) 10.46
Market Capitalization (millions) 44.58
Short Ratio NA
Last Split Date 11/9/2020
Dividend Information
Dividend Yield 0.00%
Annual Dividend $0.00
Payout Ratio NA
Change in Payout Ratio NA
Last Dividend Payout / Amount NA / $0.00

Fundamental Ratios

P/E (F1) NA
Trailing 12 Months NA
PEG Ratio NA
EPS Growth
vs. Previous Year 21.87%
vs. Previous Quarter 58.33%
Sales Growth
vs. Previous Year 164.48%
vs. Previous Quarter 247.72%
Price Ratios
Price/Book 7.93
Price/Cash Flow NA
Price / Sales 30.45
6/30/21 NA
3/31/21 -974.33
12/31/20 NA
6/30/21 NA
3/31/21 -148.91
12/31/20 -209.99
Current Ratio
6/30/21 NA
3/31/21 5.15
12/31/20 4.61
Quick Ratio
6/30/21 NA
3/31/21 5.01
12/31/20 4.49
Operating Margin
6/30/21 NA
3/31/21 -639.07
12/31/20 -804.14
Net Margin
6/30/21 NA
3/31/21 -639.14
12/31/20 -804.14
Pre-Tax Margin
6/30/21 NA
3/31/21 -639.07
12/31/20 -804.92
Book Value
6/30/21 NA
3/31/21 0.54
12/31/20 0.60
Inventory Turnover
6/30/21 NA
3/31/21 0.44
12/31/20 0.35
6/30/21 NA
3/31/21 0.00
12/31/20 0.00
Debt to Capital
6/30/21 NA
3/31/21 0.00
12/31/20 0.00